FOLH1 and prostate cancer: However, Assadi et al. observed disease stabilisation in a prostate cancer patient after 4.5 months and a single cycle of [177Lu]Lu-DOTA-FAPi-46 (1.85 GBq) [20], raising the question of whether FAPI-RLT might be a potential option for PSMA-negative patients [21].